CagriSema obesity drug: what the phase 3 data shows Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace What is cagrisema and how does it work for weight loss? Novo Nordisk's CagriSema Leads to Superior Weight Loss in REDEFINE 1 Trial Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current